{
    "root": "2f881a90-dfd9-314d-e063-6294a90a6f9a",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "PYLARIFY",
    "value": "20250304",
    "ingredients": [
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "ISOTONIC SODIUM CHLORIDE SOLUTION",
            "code": "VR5Y7PDT5W"
        },
        {
            "name": "PIFLUFOLASTAT F-18",
            "code": "3934EF02T7"
        }
    ],
    "indications": "pylarify indicated positron emission tomography ( pet ) prostate-specific membrane antigen ( psma ) positive lesions men prostate cancer : suspected metastasis candidates initial definitive therapy . suspected recurrence based elevated serum prostate-specific antigen ( psa ) level .",
    "contraindications": "recommended dose 333 mbq ( 9 mci ) acceptable range 296 mbq 370 mbq ( 8 mci 10 mci ) , administered bolus intravenous injection . ( 2.2 ) initiate imaging approximately 60 minutes pylarify . patient void immediately prior initiation imaging . image acquisition start mid-thigh proceed skull vertex . ( 2.3 , 2.4 ) full prescribing information additional preparation , handling , , imaging , radiation dosimetry information . ( 2 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "PYLARIFY is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:\n                  \n                     with suspected metastasis who are candidates for initial definitive therapy.\n                     with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.",
    "contraindications_original": "Recommended dose is 333 MBq (9 mCi) with an acceptable range of 296 MBq to 370 MBq (8 mCi to 10 mCi), administered as a bolus intravenous injection. ( 2.2 ) Initiate imaging approximately 60 minutes after PYLARIFY administration. The patient should void immediately prior to initiation of imaging. Image acquisition should start from mid-thigh and proceed to the skull vertex. ( 2.3 , 2.4 ) See full prescribing information for additional preparation, handling, administration, imaging, and radiation dosimetry information. ( 2 )",
    "adverseReactions_original": "None."
}